ABSTRACT In this era of nanotechnology lyotropic liquid crystalline nanoparticles (cubosomes) are relatively less explored lipid-based nanocarriers that can be formulated selectively and specificity for almost all administration routes. The natural compounds are proved to be significantly curative in pulmonary diseases due to reported anti-oxidant, antiinflammatory and immunomodulatory activities. The natural products have limited bioavailability due to either hydrophilic or low water solubility. These limitations can be overcome by using a novel nanotechnology such as cubosomes or liquid crystalline nanoparticles (LCNs). LCNs can easily encapsulate both hydrophilic and hydrophobic compounds because of the amphiphilic nature of lipid monoolein (MO). LCN can be used to co-deliver synthetic and natural compounds irrespective of their solubility due to multicompartment structure. We can use LCNs to formulate drugs of synthetic origin with natural one to overcome multidrug resistance (MDR).